Solid Tumors/Non-Hematological



CBL0137 is a small molecule in the carbazole family affecting p53 and NF-kappa B signal transduction pathways. It is administered intravenously on days 1, 8 and 15 every 28 days in patients with metastatic or advanced solid tumors and refractory lymphomas.

Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Category: Solid Tumors/Non-Hematological
Contact: Epp Goodwin at (210) 450-5798